Vijaya Iyer, PhD,  —

Vijaya Iyer is a freelance science writer with BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, and more. She received her PhD in Microbiology from Kansas State University. Her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University. She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.

Articles by Vijaya Iyer

CARSTAR Earns Fundraising Awards from Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation (CFF) recognized CARSTAR — the largest franchise network of auto body repair service in North America — as one of its National Corporate Champions of the year for raising more than $100,000 toward cystic fibrosis (CF) research and care. CARSTAR also received the Rising Star…

Synspira’s CF Therapy Candidate SNSP113 Granted Orphan Drug Status in EU

Synspira Therapeutics’s candidate for treating cystic fibrosis, SNSP113, has received orphan drug designation from the European Medicines’ Agency (EMA) in the European Union. The status was granted by the EMA’s Committee for Orphan Medicinal Products (COMP), which reviews experimental treatments developed for rare diseases. Thick mucus accumulates…

Lung Enzyme Cathepsin S is New Therapeutic Target for CF and COPD

Blocking the enzyme cathepsin S can alleviate symptoms and reduce lung damage in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), according to multinational teams led by researchers at Queen’s University Belfast, U.K. The findings on CF were reported in the study “Targeting of Cathepsin…

ContraFect Granted Up to $6.94M to Develop Novel Therapy Against ESKAPE Pathogens

ContraFect will receive up to $6.94 million in funding from CARB-X to support the development of their proprietary therapeutic peptides — amurins — against antibiotic-resistant bacterial infections caused by gram-negative ESKAPE pathogens. The company intends to develop these compounds as potential therapies for pulmonary exacerbations of cystic fibrosis and hospital-acquired…